Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/182343
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baiges Aznar, Anna | - |
dc.contributor.author | Cerda, Eira | - |
dc.contributor.author | Amicone, Caroline | - |
dc.contributor.author | Tellez, Luis | - |
dc.contributor.author | Alvarado Tapias, Edilmar | - |
dc.contributor.author | Puente, Angela | - |
dc.contributor.author | Fortea, Jose Ignacio | - |
dc.contributor.author | Llop, Elba | - |
dc.contributor.author | Rocha, Filipa | - |
dc.contributor.author | Orts, Lara | - |
dc.contributor.author | Ros Fargas, Olivia | - |
dc.contributor.author | Vizcarra, Pamela | - |
dc.contributor.author | Zekrini, Kamal | - |
dc.contributor.author | Amara Lounes, Ould | - |
dc.contributor.author | Touati, Ghiles | - |
dc.contributor.author | Jimenez, Natalia | - |
dc.contributor.author | Serrano, Maria Jose | - |
dc.contributor.author | Falgà, Àngels | - |
dc.contributor.author | Magaz Martínez, Marta | - |
dc.contributor.author | Olivas, Pol | - |
dc.contributor.author | Betancourt, Fabian | - |
dc.contributor.author | Pérez Campuzano, Valeria | - |
dc.contributor.author | Turon, Fanny | - |
dc.contributor.author | Payancé, Audrey | - |
dc.contributor.author | Goria, Odile | - |
dc.contributor.author | Rautou, Pierre Emmanuel | - |
dc.contributor.author | Hernández Gea, Virginia | - |
dc.contributor.author | Villanueva, Candid | - |
dc.contributor.author | Albillos, Agustín | - |
dc.contributor.author | Plessier, Aurélie | - |
dc.contributor.author | García Pagán, Juan Carlos | - |
dc.date.accessioned | 2022-01-13T18:28:11Z | - |
dc.date.available | 2022-12-26T06:10:22Z | - |
dc.date.issued | 2021-12-26 | - |
dc.identifier.uri | http://hdl.handle.net/2445/182343 | - |
dc.description.abstract | Vascular liver diseases (VLD) are represented mainly by portosinusoidal vascular disease (PSVD), non-cirrhotic splanchnic vein thrombosis (SVT) and Budd Chiari syndrome (BCS). It is unknown whether patients with VLD constitute a high-risk population for complications and greater COVID-19-related mortality from SARS-CoV-2 infection. Our objective was to assess the prevalence and severity of SARS-CoV-2 infection among patients with VLD, as well as to assess its impact on hepatic decompensation and survival.This is a observational international study analyzing the prevalence and severity of SARS-CoV-2 infection in VLD between March 2020-March 2021 comparing with the general population (GP). Patients from Spain (5 centers, n = 493) and France (1 center, n = 475) were included.Nine hundred and sixty-eight patients were included: 274 PSVD, 539 SVT and 155 BCS. Among them, 138 (14%) were infected with SARS-CoV-2: 53 PSVD, 77 SVT and 8 BCS. The prevalence of SARS-CoV-2 infection in PSVD (19%) and SVT (14%) was significantly higher than in GP (6.5%, p < 0.05), while it was very similar in BCS (5%). In terms of infection severity, patients with VLD also presented a higher need of hospital admission (14% vs 7.3%, p<0.01), ICU admission (2% vs 0.7%, p< 0.01) and mortality (4% vs 1.5%, p < 0.05) than GP. Previous history of ascites (50% vs 8%, p < 0.05) and post-COVID-19 hepatic decompensation (50% vs 4%, p < 0.05) were associated to COVID-19 mortality.PSVD and SVT patients could be at higher risk of infection by SARS-CoV-2 and at higher risk of severe COVID-19 disease.Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved. | ca |
dc.format.extent | 33 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | W.B. Saunders | ca |
dc.relation.isformatof | versió postprint del document publicat a: https://doi.org/10.1016/j.cgh.2021.12.032 | - |
dc.relation.ispartof | Clinical Gastroenterology And Hepatology, 2021 | - |
dc.relation.uri | https://doi.org/10.1016/j.cgh.2021.12.032 | - |
dc.rights | cc by-nc-nd (c) AGA Institute, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Malalties vasculars | - |
dc.subject.classification | Malalties del fetge | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Vascular diseases | - |
dc.subject.other | Liver diseases | - |
dc.title | Impact of SARS-CoV-2 pandemic on vascular liver diseases | - |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2022-01-13T15:25:51Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9295622 | - |
dc.identifier.pmid | 34968728 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_9295622_pre-proof_-_impact_of_sars-cov-2_pandemic_on_vascular_liver_deseases.pdf | 1.26 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License